Department of Anesthesiology, Vanderbilt University School of Medicine Nashville, TN, USA.
Front Pharmacol. 2011 Nov 30;2:75. doi: 10.3389/fphar.2011.00075. eCollection 2011.
The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family members exhibiting broad and often overlapping cellular, tissue, or organ distributions. The discovery of disease-causing mutations in humans and experiments on knockout mice has underscored the importance of Kir channels in physiology and in some cases raised questions about their potential as drug targets. However, the paucity of potent and selective small-molecule modulators targeting specific family members has with few exceptions mired efforts to understand their physiology and assess their therapeutic potential. A growing body of evidence suggests that G protein-coupled inward rectifier K (GIRK) channels of the Kir3.X subfamily may represent novel targets for the treatment of atrial fibrillation. In an effort to expand the molecular pharmacology of GIRK, we performed a thallium (Tl(+)) flux-based high-throughput screen of a Kir1.1 inhibitor library for modulators of GIRK. One compound, termed VU573, exhibited 10-fold selectivity for GIRK over Kir1.1 (IC(50) = 1.9 and 19 μM, respectively) and was therefore selected for further study. In electrophysiological experiments performed on Xenopus laevis oocytes and mammalian cells, VU573 inhibited Kir3.1/3.2 (neuronal GIRK) and Kir3.1/3.4 (cardiac GIRK) channels with equal potency and preferentially inhibited GIRK, Kir2.3, and Kir7.1 over Kir1.1 and Kir2.1.Tl(+) flux assays were established for Kir2.3 and the M125R pore mutant of Kir7.1 to support medicinal chemistry efforts to develop more potent and selective analogs for these channels. The structure-activity relationships of VU573 revealed few analogs with improved potency, however two compounds retained most of their activity toward GIRK and Kir2.3 and lost activity toward Kir7.1. We anticipate that the VU573 series will be useful for exploring the physiology and structure-function relationships of these Kir channels.
内向整流钾通道家族(Kir)由至少 16 个家族成员组成,这些成员在细胞、组织或器官中具有广泛而通常重叠的分布。在人类中发现致病突变以及对敲除小鼠的实验强调了 Kir 通道在生理学中的重要性,并且在某些情况下提出了它们作为药物靶点的潜力的问题。然而,针对特定家族成员的有效且选择性的小分子调节剂的缺乏除了极少数例外,使得理解它们的生理学和评估它们的治疗潜力的努力陷入困境。越来越多的证据表明,Kir3.X 亚家族的 G 蛋白偶联内向整流钾(GIRK)通道可能代表治疗心房颤动的新靶标。为了扩展 GIRK 的分子药理学,我们对 Kir1.1 抑制剂文库进行了基于铊(Tl(+))通量的高通量筛选,以寻找 GIRK 的调节剂。一种称为 VU573 的化合物对 GIRK 的选择性比 Kir1.1 高 10 倍(IC(50)分别为 1.9 和 19 μM),因此被选为进一步研究的对象。在 Xenopus laevis 卵母细胞和哺乳动物细胞上进行的电生理实验中,VU573 对 Kir3.1/3.2(神经元 GIRK)和 Kir3.1/3.4(心脏 GIRK)通道具有同等的抑制作用,并优先抑制 GIRK、Kir2.3 和 Kir7.1 超过 Kir1.1 和 Kir2.1。建立了 Tl(+)通量测定法用于 Kir2.3 和 Kir7.1 的 M125R 孔突变体,以支持开发这些通道更有效和选择性的类似物的药物化学工作。VU573 的结构-活性关系揭示了一些具有更高效力的类似物,但是两种化合物保留了对 GIRK 和 Kir2.3 的大部分活性,并且对 Kir7.1 失去了活性。我们预计 VU573 系列将有助于探索这些 Kir 通道的生理学和结构-功能关系。